{
    "nctId": "NCT05512780",
    "briefTitle": "Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage \u2161-\u2162 HR-positive/HER2-negative Breast Cancer",
    "officialTitle": "An Exploratory Clinical Study of CDK4/6 Inhibitor Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage \u2161-\u2162 HR-positive/HER2-negative Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Solid Tumor",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 30,
    "primaryOutcomeMeasure": "ORR",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* 1. Postmenopausal women aged \u226518 years, the definition of postmenopausal:\n\n  1. the patients with the history of bilateral oophorectomy, or age \u2265 60 years; or\n  2. Age \\<60, natural postmenopausal state (defined as the spontaneous cessation of regular menstruation for at least 12 consecutive months, without other pathological or physiological causes), E2 and FSH at the postmenopausal levels 2. All patients were estrogen receptor (ER) positive (\\>10%), HER2 -negative invasive breast cancer regardless of PR expression level. Immunohistochemistry (IHC) score of 0+, or 2+ confirmed by pathology laboratory and negative in situ hybridization (ISH) test (HER-2/CEP17 ratio \\<2.0); 3. Treatment-naive patients with stage \u2161-\u2162 tumors whose tumor staging meets the criteria of the 8th edition of the American Joint Committee on Cancer (AJCC) Staging;\n\nExclusion Criteria:\n\n* 1. Received any form of anti-tumor therapy (chemotherapy, radiotherapy, molecular targeted therapy, endocrine therapy, etc.) 2. Concurrently receiving any other anti-tumor therapy that those specified in the protocol; 3. Bilateral breast cancer, inflammatory breast cancer, or occult breast cancer; 4. Stage \u2163 breast cancer;",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}